CN103356627B - Use of drug in treatment on candida glabrata infected diseases - Google Patents
Use of drug in treatment on candida glabrata infected diseases Download PDFInfo
- Publication number
- CN103356627B CN103356627B CN201310332527.XA CN201310332527A CN103356627B CN 103356627 B CN103356627 B CN 103356627B CN 201310332527 A CN201310332527 A CN 201310332527A CN 103356627 B CN103356627 B CN 103356627B
- Authority
- CN
- China
- Prior art keywords
- drug
- candida glabrata
- compound
- treatment
- pyrazolopyrimidine compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a use of a pyrazolopyrimidine compound in treatment on candida glabrata infected diseases. The pyrazolopyrimidine compound is N3-(4-fluoropentyl)-1H-pyrazolo[3,4-D]pyrimidine-3,4-diamine. The pyrazolopyrimidine compound has good activity of resisting various shallow and deep fungi. Compared with the existing antifungal drugs in clinical application, the pyrazolopyrimidine compound has the advantages of high efficiency, low toxicity and wide antifungal spectrum and can be used for preparation of antifungal drugs.
Description
Technical field
The present invention relates to a kind of compound application, specifically, is the application about a kind of throat azoles miazines compound.
Background technology
The position that fungal infectious disease is invaded human body according to fungus is divided into 4 classes: superficial fungi disease, dermatomycosis, subcutaneous mycosis and systemic mycoses; The former two is collectively referred to as superficial mycosis, and the latter two are called again deep mycosis.Fungal infectious disease is divided into following several according to fungal infection difference: candida albicans bacterium infectious disease, Candida parapsilosis bacterium infectious disease, Candida glabrata infectious disease, infection by Cryptococcus neoformans disease, Gypsum Fibrosum shape sporidiole bacteria infectious disease, trichophyton infectious disease, aspergillus fumigatus infection disease.
In recent years, along with the extensive use of broad ectrum antibiotic, corticosteroid and immunosuppressant, advanced Clinics is as the popularization of organ transplantation etc., AIDS's is popular, and the impact of tumor Radiotherapy chemotherapy, cause fungal infection particularly deep fungal infection significantly rise, deep fungal infection has now become the major disease such as acquired immune deficiency syndrome (AIDS) and tumor main causes of death.
Reported at present and clinically conventional nitrogen azole compounds have ketoconazole (Ketoconazole, KCZ), fluconazol (Fluconazole, FCZ), voriconazole (Voriconazole, VCZ), itraconazole (Itraconazole, ICZ), amphotericin B (Amphotericin B, AMB) etc., but these compounds still exist, and above-mentioned toxic and side effects is large, narrow antimicrobial spectrum, easily produce the defects such as drug resistance, for example bring into play the required dosage of drug effect larger, thereby can produce larger toxic and side effects to human body.。
Summary of the invention
The object of the invention is for deficiency of the prior art, provide a kind of medicine to apply at Candida glabrata infectious disease.
For achieving the above object, the technical scheme that the present invention takes is: a kind of throat azoles miazines compound is in the application of preparing in Candida glabrata infectious disease medicament, described throat azoles miazines compound is N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen.
The invention has the advantages that: compound of the present invention has good antifungal activity to various superficial parts and deep fungal, compared with the antifungal drug of existing clinical practice, to there is the advantages such as efficient, hypotoxicity, anti-fungus spectra be wide, can be used for preparing antifungal drug.
Detailed description of the invention
Below detailed description of the invention provided by the invention is elaborated.
Embodiment 1
Below detailed description of the invention provided by the invention is elaborated.
(1) experimental technique: adopt conventional In Vitro Bacteriostasis experimental technique (to refer to: Antimicrob Agents Chemother 1995,39 (5): 1169)
1. materials and methods
(1) testing compound of the present invention: N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen
The experiment of particular compound:
Buy the Tocris Bioscience(U.S., Ellisville) ready-made compound (Cat. No. 2731) carries out cytologic experiment, and specifying information is as follows:
CGP57380，CAS?number：522629-08-9
Molecular weight: 244.23
Chemical name: N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen (N3-(4-Fluorophenyl)-1H-pyrazolo-[3,4-d] pyrimidine-3,4-diamine)
Molecular formula: C
11h
9fN
6.
Experimental strain is as follows:
This experiment has selected following 8 kinds of common human body cause illness's standard fungal bacterial strains as screening object:
Table 1 antifungal activity in-vitro screening strain subject
(2) test method
Bacteria suspension preparation: above-mentioned fungus is cultivated 16 hours through 35 DEG C of YEPD fluid mediums, twice activation, with blood cell counting plate counting, adjusts bacteria concentration to 1 × 10 with RPM1640 fluid medium
4～1 × 10
5individual/mL.
Medicinal liquid preparation: get testing compound of the present invention and be dissolved in dimethyl sulfoxine, be made into the medicine storage liquid of 8.0mg/mL, be diluted to 640 μ g/mL with RPM1640 before experiment.
Inoculation: get drug sensitive plate, add RPMI RPMI-1640 200 μ l in No. 1 hole of every row, make blank; No. 12 hole adds bacterium liquid 200 μ l to be measured, makes negative control; 2 ~ No. 11 holes of the every row of drug sensitive plate add respectively bacterium liquid 180 μ l, fully mix, and make the final drug level in each hole be respectively 64,32,16,8,4,2,1,0.5,0.25 and 0.125 μ g/ml, and in each hole, DMSO content is all lower than 1%; Positive control, not containing medicine, is made in No. 12 holes.Control drug is fluconazol (FCZ), itraconazole (ICZ), voriconazole (VCZ), ketoconazole (KCZ), terbinafine (TBR), amphotericin B (AMB).
Cultivate and detect: establishing positive control hole optical density value (OD value) is 100%, taking optical density value than positive control hole lower than 80% lowest concentration of drug as minimal inhibitory concentration value (MIC
80).
(2) experimental result
In Vitro Bacteriostasis experimental result is in table 2.
Table 2 the compounds of this invention is to common pathomycete external activity (MIC, μ g/ml)
| Compound | Y0109 | SC5314 | Nearly flat 22019 | New hidden 32609 | Smooth 537 | Cigarette song 07544 | Red hair Cmccftla | The little Cmccfmza of stone |
| c1 | 8 | 8 | 2 | 1 | 1 | >64 | >64 | >64 |
| ICZ | 8 | 4 | 8 | 4 | 8 | 8 | 2 | 2 |
| TRB | 64 | 32 | 1 | 1 | 4 | 0.5 | 0.125 | 0.0625 |
| KCZ | 0.25 | 0.25 | 0.5 | 0.125 | 0.5 | 8 | 1 | 1 |
| VCZ | 0.03125 | 0.0625 | 0.03125 | 0.0156 | 0.03125 | 0.25 | 0.03125 | 0.125 |
| AMB | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 0.125 |
| FCZ | 0.5 | 0.5 | 1 | 1 | 1 | >64 | 8 | 8 |
Note: KCZ. ketoconazole, FCZ. fluconazol, VCZ. Wo Likang azoles, ICZ. itraconazole, TRB. terbinafine, AMB amphotericin
Above-mentioned experimental result shows that compound of the present invention has good antifungal activity, and compound is all far better than fluconazol to the vitro inhibition activity of selected fungus, illustrates that the compounds of this invention can be used for preparing the medicine of anti-fungal infection.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and the supplementary protection scope of the present invention that also should be considered as.
Claims (1)
1. throat azoles miazines compound is in an application of preparing in Candida glabrata infectious disease medicament, and described throat azoles miazines compound is N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310332527.XA CN103356627B (en) | 2013-08-02 | 2013-08-02 | Use of drug in treatment on candida glabrata infected diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310332527.XA CN103356627B (en) | 2013-08-02 | 2013-08-02 | Use of drug in treatment on candida glabrata infected diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356627A CN103356627A (en) | 2013-10-23 |
| CN103356627B true CN103356627B (en) | 2014-10-29 |
Family
ID=49359444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310332527.XA Expired - Fee Related CN103356627B (en) | 2013-08-02 | 2013-08-02 | Use of drug in treatment on candida glabrata infected diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356627B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102869669A (en) * | 2010-02-26 | 2013-01-09 | 贝林格尔.英格海姆国际有限公司 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
-
2013
- 2013-08-02 CN CN201310332527.XA patent/CN103356627B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102869669A (en) * | 2010-02-26 | 2013-01-09 | 贝林格尔.英格海姆国际有限公司 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356627A (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150366845A1 (en) | Pharmaceutical composition for diseases caused by pathogenic microorganisms such as aspergillus | |
| CN105193808A (en) | Synergistic drug effect of combination of BDSF and itraconazole on clinical drug-resistant candida albicans | |
| Bormann et al. | Review of the pharmacology and clinical studies of micafungin | |
| CN103356627B (en) | Use of drug in treatment on candida glabrata infected diseases | |
| CN103356625B (en) | Use of pyrazolopyrimidine compound in treatment on candida parapsilosis infected diseases | |
| CN103356628B (en) | Use of pyrazolopyrimidine compound in pharmacy | |
| JP2020529999A (en) | Antifungal agent showing enhanced activity at acidic pH | |
| CN103405439B (en) | Application of pyrimidine compound to preparing antifungal medicines | |
| CN103356626B (en) | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases | |
| CN103356624B (en) | Use of pyrimidine compound in antifungal drugs | |
| CN103417545B (en) | Application of pyrazolopyrimidine compound in preparing medicines for aspergillus fumigatus infectious diseases | |
| TW201842915A (en) | Antifungal agents used in combination | |
| Khan et al. | Antifungal potential of disulfiram | |
| Werbel et al. | Angioinvasive, cutaneous infection due to Colletotrichum siamense in a stem cell transplant recipient: Report and review of prior cases | |
| CN103565794A (en) | Application of 7-hydroxy-4'-methoxyisoflavone in antifungal medicament | |
| CN103585143A (en) | Application of formononetin in preparation of aspergillus fumigatus resistant medicament | |
| RU2497521C1 (en) | Pharmaceutical composition possessing antifungal activity, and method for preparing it | |
| CN110090217A (en) | A kind of pharmaceutical composition and its application in preparation of anti-tumor drugs | |
| CN103565791A (en) | Application of formononetin in trichophyton rubrum | |
| CN103565790A (en) | Application of formononetin in cryptococcus neoformans | |
| CN103565795A (en) | Application of formononetin in antifungal medicaments | |
| CN103565793A (en) | Application of formononetin in antifungal medicaments | |
| CN103565792A (en) | Application of formononetin in microsporum gypseum | |
| CN107812011A (en) | A kind of antimycotic pharmaceutical composition | |
| Wafer et al. | Trichophyton tonsurans associated tinea corporis infection with the development of Majocchi's granuloma in a renal transplant patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI TENTH PEOPLE'S HOSPITAL Free format text: FORMER OWNER: TAICANG SHENGZHOU BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20140915 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215434 SUZHOU, JIANGSU PROVINCE TO: 200072 PUTUO, SHANGHAI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140915 Address after: 200072 No. 301, Yanchang Road, Shanghai Applicant after: Shanghai Tenth People's Hospital Address before: 215434 room 20, building 151, middle Town, pontoon bridge, Taicang, Jiangsu, Suzhou Applicant before: Taicang City Shengzhou Biological Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141029 Termination date: 20180802 |